Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however treatment outcomes in real-world clinical practice remains unclear. Methods: This retro...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AME Publishing Company
2024
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/44420/3/Does%20dose.pdf http://ir.unimas.my/id/eprint/44420/ https://tlcr.amegroups.org/article/view/83673/html https://dx.doi.org/10.21037/tlcr-23-691 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|